Board certified in Internal Medicine and Pulmonary Disease
Areas of Interest: Critical care/cardiac arrest simulation training, COPD/asthma, lung cancer diagnosis
Pulmonary and Critical Care Medicine Fellowship: Creighton University School of Medicine, Omaha, NE
Residency: SSM Saint Mary’s Health Center, St. Louis, MO
Medical School: American University of Antigua College of Medicine
Medicine
Associate Professor
Sub Investigator - GSK COPD CTT116855: A phase III, 52 week, randomized, double-blind, 3-arm parallel group study, comparing the efficacy, safety and tolerability of the fixed dose triple combination FF/UMEC/VI with the fixed dose dual combinations of FF/VI and UMEC/VI, al administered once-daily in the morning via a dry powder inhaler in subjects with chronic obstructive pulmonary disease
Sub Investigator - Insmed MAC: A Randomized, Open-Label, Multicenter Study of Liposomal Amikacin for Inhalation (LAI) in Adult Patients with Nontuberculous Mycobacterial (NTM) Lung Infections caused by Mycobacterium avium complex (MAC) that are refractory to treatment
Sub Investigator - Janssen: Medically Ill Patient Assessment of Rivaroxaban Versus Placebo IN Reducing Post-Discharge Venous Thrombo-Embolism Risk (MARINER)
Sub Investigator: CXA-NP-11-04: A Prospecteive, Randomized, Double Blind, Multicenter, Phase III Study to Assess the Safety and Efficacy of Intravenous Ceftolozane/Tazobactam Compared with Meropenem in Adult Patients with Ventilated Nosocomial Pneumonia.
Sub Investigator AstraZeneca: Double-Blind, Randomized, Placebo-controlled, Parallel-group, Phase IV Study to Evaluate the Effect of Aclidinuim Bromide on Long-Term Cardiovascular Safety and COPD Exacerbations in Patients with Moderate to Very Severe COPD (ASCENT COPD)
Sub Investigator - AstraZeneca: A Randomized, Double-blind, double dummy, chronic dosing (56 week) Placebo-controlled, Parallel Group, Multicentre, Phase III Study to evaluate the efficacy and safety of 3 doses of Benralizumab in patients with moderate to very severe chronic
obstructive pulmonary disease with a history of COPD exacerbations